Personal information

Countries

United Kingdom

Activities

Collapse all

Employment (7)

UCLP: London, GB

2014 to present | AHSC Programme Director (Infection, Immunity and Inflammation )
Employment
Source: Self-asserted source
Hans J Stauss

UCL Division of Infection & Immunity: London , GB

2013 to present | Co-director (Infection and Immunity )
Employment
Source: Self-asserted source
Hans J Stauss

Institute of Immunity and Transplantation : London, GB

2013 to present | Director (Immunology)
Employment
Source: Self-asserted source
Hans J Stauss

Royal Free Hospital: London, London, GB

2011 to present | Governor
Employment
Source: Self-asserted source
Hans J Stauss

University College London: London, London, GB

2010 to present | Head of Research Department of Immunology (Immunology )
Employment
Source: Self-asserted source
Hans J Stauss

Royal Free Hospital: London, London, GB

2005 to 2016 | Head of Clinical Immunology (Immunology )
Employment
Source: Self-asserted source
Hans J Stauss

UCLP : London , GB

2009 to 2014 | UCLP Programme Director (Immunology and Transplantation)
Employment
Source: Self-asserted source
Hans J Stauss

Education and qualifications (5)

Royal College of Pathologists: London, London, GB

2007 to 2009 | FRCPath
Qualification
Source: Self-asserted source
Hans J Stauss

University of Chicago: Chicago, IL, US

1987 to 1990 | PhD (Committee on Immunology )
Qualification
Source: Self-asserted source
Hans J Stauss

Educational Commission for Foreign Medical Graduates: Philadelphia, PA, US

1983 to 1987 | US diploma
Qualification
Source: Self-asserted source
Hans J Stauss

University of Freiburg: Freiburg, Baden-Württemberg, DE

1982 to 1983 | MD (Faculty of Medicine )
Qualification
Source: Self-asserted source
Hans J Stauss

University of Freiburg: Freiburg, Baden-Württemberg, DE

1982 to 1983 | D.M.Sci (Faculty of Medicine )
Qualification
Source: Self-asserted source
Hans J Stauss

Funding (11)

Dominant TCR Programme

2017-01 to 2020-01 | Grant
Cell Medica (London , GB)
Source: Self-asserted source
Hans J Stauss

Engineered Treg Therapy for Multiple Sclerosis

2016-05 to 2018-04 | Grant
Wellcome Trust (London , GB)
Source: Self-asserted source
Hans J Stauss

Characterising viral antibody evasion by conformational masking.

2015-10 to 2020-09 | Grant
Wellcome Trust (London, GB)
Source: Self-asserted source
Hans J Stauss

Natural killer cell subsets in the liver: phenotype, function and role in obesity-induced liver disease

2015-03 to 2020-02 | Grant
Wellcome Trust (Wellcome Trust Sir Henry Dale, GB)
Source: Self-asserted source
Hans J Stauss

The NKG2D pathway in hepatitis B associated hepatocellular carcinoma in a highly endemic setting

2014-04 to 2018-03 | Grant
Wellcome Trust (London , GB)
Source: Self-asserted source
Hans J Stauss

Purchase of a confocal microscope

2014-04 to 2015-06 | Grant
Wellcome Trust (London , GB)
Source: Self-asserted source
Hans J Stauss

Editing specificity and function to enhance T cell therapy of haematological malignancies

2013-06 to 2018-05 | Grant
LLR (London , GB)
Source: Self-asserted source
Hans J Stauss

The Institute of Immunity and Transplantation

2013-03 to 2018-04 | Award
UK research partnership investment (London , GB)
Source: Self-asserted source
Hans J Stauss

Adoptive engineered T-cell Trials to Achieve Cancer Killing [ATTACK]

2012-10 to 2017-10 | Grant
European Union (London , GB)
GRANT_NUMBER:

305863
Source: Self-asserted source
Hans J Stauss

MRC Medical Molecular Virology Centre Grant

2010-01 to 2015-01 | Grant
Medical Research Council (London , GB)
Source: Self-asserted source
Hans J Stauss

CMV TCR Gene Therapy. A phase I/II safety, toxicity and feasibility study of adoptive immunotherapy in allo-HSCT

2009-06 to 2015-05 | Grant
Medical Research Council (London , GB)
Source: Self-asserted source
Hans J Stauss

Works (24)

Synthetic Cell-Based Immunotherapies for Neurologic Diseases

Neurology Neuroimmunology & Neuroinflammation
2023-09 | Journal article
DOI: 10.1212/NXI.0000000000200139
Contributors: Louisa von Baumgarten; Hans J. Stauss; Jan D. Lünemann
Source: check_circle
Crossref

Forced Fox-P3 expression can improve the safety and antigen-specific function of engineered regulatory T cells

Journal of Autoimmunity
2022-10 | Journal article
DOI: 10.1016/j.jaut.2022.102888
Contributors: Jenny McGovern; Angelika Holler; Sharyn Thomas; Hans J. Stauss
Source: check_circle
Crossref

Transitional B cell cytokines predict renal allograft outcomes

Science Translational Medicine
2021-02-24 | Journal article
DOI: 10.1126/scitranslmed.abe4929
Contributors: Aravind Cherukuri; Alan D. Salama; Rajil Mehta; Kanishka Mohib; Leting Zheng; Ciara Magee; Mark Harber; Hans Stauss; Richard J. Baker; Amit Tevar et al.
Source: check_circle
Crossref

CRISPR-mediated deletion of the Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) improves human T cell function for adoptive T cell therapy

2020-12-04 | Preprint
DOI: 10.1101/2020.12.03.410043
Contributors: Sonja Prade; David Wright; Nicola Logan; Alexandra R. Teagle; Hans Stauss; Rose Zamoyska
Source: check_circle
Crossref

Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity

Journal of Clinical Investigation
2020-03-09 | Journal article
DOI: 10.1172/JCI133102
Contributors: Simone Dertschnig; Pamela Evans; Pedro Santos e Sousa; Teresa Manzo; Ivana R. Ferrer; Hans J. Stauss; Clare L. Bennett; Ronjon Chakraverty
Source: check_circle
Crossref

Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells.

Oncoimmunology
2018-12-05 | Journal article
DOI: 10.1080/2162402X.2018.1542917
PMID: 30723575
PMC: PMC6350686
Source: Self-asserted source
Hans J Stauss

Mediated Deletion of PTPN22 in Jurkat T Cells Enhances TCR Signaling and Production of IL-2

Frontiers in Immunology
2018-11-12 | Journal article
Source: Self-asserted source
Hans J Stauss

Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver

Molecular Therapy
2018-11-07 | Journal article
Source: Self-asserted source
Hans J Stauss

Redirection to the bone marrow improves T cell persistence and antitumor functions

Journal of Clinical Investigation
2018-04-09 | Journal article
Source: Self-asserted source
Hans J Stauss

Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma

Molecular Therapy
2018-03-16 | Journal article
Source: Self-asserted source
Hans J Stauss

Investigating the Effectiveness, Acceptability and Impact on Healthcare Usage of Providing a Cognitive-Behavioural Based Psychological Therapy Service for Patients with Primary Antibody Deficiency

Journal of Clinical Immunology
2018-02 | Journal article
Source: Self-asserted source
Hans J Stauss

Study of an extended family with CTLA-4 deficiency suggests a CD28/CTLA-4 independent mechanism responsible for differences in disease manifestations and severity

Clinical Immunology
2018-01-03 | Journal article
Source: Self-asserted source
Hans J Stauss

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations

Blood
2017-03-16 | Journal article
Source: Self-asserted source
Hans J Stauss

No hiding place for BOB inside myeloma

Blood
2017-03-09 | Journal article
DOI: 10.1182/blood-2017-01-761510
Contributors: Hans J. Stauss
Source: check_circle
Crossref

Differences in systemic adaptive immunity contribute to the 'frequent exacerbator' COPD phenotype

Respiratory Research
2016-10-28 | Journal article
Source: Self-asserted source
Hans J Stauss

Expression of a dominant T cell receptor can reduce toxicity and enhance tumor protection of allogeneic T cell therapy

Haematologica
2016-04 | Journal article
Source: Self-asserted source
Hans J Stauss

An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mis-pairing with endogenous TCRs in human T-cells

Oncotarget
2016-04-19 | Journal article
Source: Self-asserted source
Hans J Stauss

High dimensional immune monitoring identifies PD1-expressing T cell subsets as a risk factor for rejection episodes in renal transplant patients

Frontiers in Immunology
2016-04-11 | Journal article
Source: Self-asserted source
Hans J Stauss

The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1

Journal of Clinical Immunology
2016-01 | Journal article
Source: Self-asserted source
Hans J Stauss

Genetic regulation of fate decisions in therapeutic T cells to enhance tumor protection and memory formation

Cancer Research
2015-07-01 | Journal article
Source: Self-asserted source
Hans J Stauss

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells targeting HBsAg in a liver transplant patient

Journal of Hepatology
2015-02 | Journal article
Source: Self-asserted source
Hans J Stauss

CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor

The Journal of Immunology
2015-02-01 | Journal article
Source: Self-asserted source
Hans J Stauss

CD3 limits the efficacy of TCR gene therapy in vivo.

Blood
2011-07-12 | Journal article
DOI: 10.1182/blood-2011-04-346338
PMID: 21750319
Source: Self-asserted source
Hans J Stauss

Paired comparison of platelet concentrates prepared from platelet-rich plasma and buffy coats using a new technique with 111In and 51Cr.

Transfusion
1992-02-01 | Journal article
DOI: 10.1046/j.1537-2995.1992.32292180138.x
PMID: 1542917
Source: Self-asserted source
Hans J Stauss

Peer review (5 reviews for 3 publications/grants)

Review activity for Cancer immunology and immunotherapy. (2)
Review activity for Nature (2)
Review activity for Nature immunology. (1)
How many people are using ORCID?